SUPPLEMENTAL INFORMATION

Title: TILRR (Toll-like interleukin-1 receptor regulator), an important modulator of inflammatory responsive genes, is circulating in the blood

Mohammad Abul Kashem^{1,2,3,4}, Xin-Yong Yuan⁴, Lin Li², Joshua Kimani⁵, Francis A Plummer^{1††}, Ma Luo^{1,2,4*}

Authors' affiliation(s):

¹Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, Canada.

²JC Wilt Infectious Diseases Research Centre, Winnipeg, MB, Canada.

³Department of Microbiology and Veterinary Public Health, Chittagong Veterinary and Animal Sciences University, Chittagong, Bangladesh.

⁴National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada. ⁵Institute for Tropical and Infectious Diseases, University of Nairobi, Nairobi, Kenya.

Running Title: TILRR is detected in blood

^{††} In memoriam

*Correspondence to: Ma Luo, PhD

JC Wilt Infectious Diseases Research Center, National Microbiology Laboratory, 745 Logan Avenue, Winnipeg, MB, R3E 3L5, Canada; Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada Phone: 204-789-5072, Fax: 204-789-2018 Email: maluo@canada.ca, Ma.Luo@umanitoba.ca




Figure S1: Diagram of FREM1 variants and recombinant proteins. A) Full-length FREM1 isoform 1; **B)** TILRR (FREM1 isoform 2); **C)** rFREM1 spD protein; and **D)** rFREM1 spF protein. FREM1, Fras-related extracellular matrix 1; TILRR, toll-like interleukin 1 receptor regulator; RGD, arginine-glycine-aspartic acid; CSPG, chondroitin sulfate proteoglycan; and GAG, glycosaminoglycan. This figure was adapted from Yuan et al. with permission.¹




Figure S2: Graphical representation of anti-FREM1 F237G12 IgG mAb cross-linking procedure with Protein G agarose beads. A) Protein G coupled agarose bead, **B)** Protein G bound with Fc region of anti-FREM1 F237G12 mAb, **C)** Anti-FREM1 F237G12 mAb cross-linked with protein G agarose bead by DMP. FREM1, Fras-related extracellular matrix 1; mAb, monoclonal antibody; IgG, immunoglobulin G; DMP, Dimethyl pimelimidate dihydrochloride; and RT, room temperature.







Figure S3: Affinity purification procedure of TILRR protein. A) Anti-FREM1 F237G12 mAb cross-linked protein G agarose bead, **B)** Mixture of proteins in plasma samples, **C)** Protein of interest (TILRR) bound with Fab region of anti-FREM1 mAb, **D)** Neutralized cross-linked anti-FREM1 mAb following affinity purification of target protein, **E)** Target protein (TILRR). FREM1, Fras-related extracellular matrix 1; TILRR, toll-like interleukin 1 receptor regulator; mAb, monoclonal antibody; IgG, immunoglobulin G; and DMP, Dimethyl pimelimidate dihydrochloride.



Full-length un-cropped blot 1 (probed with F237G3 mAb)




Full-length un-cropped blot 2 (probed with F218G4 mAb)




Full-length un-cropped blot 3 (Lanes 1-8 probed with F237G3 and F218G4 mAbs as indicated in the blot). This membrane was cut into three pieces and lanes 1-8 was incubated with two antibodies separately. Lanes 9-12 used for other purposes.

Figure S4: Full-length un-cropped blots of Western blot analysis. TILRR protein was confirmed by Western blot analysis in plasma of patients' group-1, -2, -3, and 4 (patient -1[ML002492], -2[ML002802], -3[ML002442], -4[ML000326], -5[ML002170], -6[ML002443], -7[ML2292], -8[ML2772], -9[ML000109], -10[ML000887], -11[ML000893], and -12[ML001070]) using affinity-purified protein (n=12; each group shows 3 patients data). The images show the bands in the blot for TILRR protein detected by two different anti-FREM1 IgG mAbs, such as F237G3 mAb (A), F218G4 mAb (B), whereas blot 3 (C) was cut in three slices and then probed with F237G3 mAb and F218G4 mAb separately as indicated. Western blot images were acquired by Odyssey CLx imaging system (LI-COR, USA) with auto channels (both 700 and 800), 42 µm resolution, high image quality, and 0mm focal offset. A whitecolored arrowhead indicates the 70 kDa-sized TILRR protein band. Other observed bands (<70kDa or >70 kDa) in the blot could be the additional variants of FREM1 (yet uncharacterized). Patients' ID# and groups are mentioned on the top of the blots. FREM1, Frasrelated extracellular matrix 1; TILRR, toll-like interleukin 1 receptor regulator; ID#, identification number; and kDa, kiloDalton.




Full-length un-cropped Gel 1 after transfer (used for F237G3 mAb)


C Group 3 Group 3



Full-length un-cropped Gel 3 after transfer (Lanes 1-8 used for F237G3 and F218G4 mAbs as indicated in the gel). Lanes 9-12 used for other purposes.




Full-length un-cropped Gel 2 after transfer (used for F218G4 mAb)




Full-length un-cropped gel before iBlot transfer to the nitrocellulose membrane 3 after transfer (Lanes 14-15 used for other purposes)


Figure S5: Full-length un-cropped gels of Coomassie blue staining. Non-transferred proteins in the gel after and before iBlot transfer in plasma of patients' group-1, -2, -3, and 4 (patient -1[ML002492], -2[ML002802], -3[ML002442], -4[ML000326], -5[ML002170], -6[ML002443], -7[ML2292], -8[ML2772], -9[ML000109], -10[ML000887], -11[ML000893], and 12[ML001070]) (n=12; each group shows 3 patients data). Gels were used to transfer proteins onto Nitrocellulose membrane that was probed by F237G3 mAb (A), and F218G4 mAb (B), except Gel3 (C), which was used for both F237G3 and F218G4 mAbs. D) After the electrophoresis, the gel was directly stained with Coomassie blue staining without transferring to Nitrocellulose membrane. The images show the bands in the gel for the different proteins including a 70 kDa TILRR protein (White-colored arrowhead). Coomassie blue staining gel images were acquired by Odyssey CLx imaging system (LI-COR, USA) with auto channel (700 channel), 42 µm resolution, high image quality, and 0.5mm focal offset. Patients' ID# and groups are mentioned on the top of the blots. ID#, identification number; and kDa, kiloDalton.




Full-length un-cropped blot 1 (probed with F237G1 mAb)



Full-length un-cropped Gel 1 after transfer (used for F237G1 mAb)




Full-length un-cropped blot 2 (probed with F237G1 mAb). Lanes 1-4 used for other purposes.




Full-length un-cropped Gel 2 after transfer (used for F237G1 mAb). Lanes 1-4 used for other purposes.

Figure S6: Western blot verification of full-length FREM1 protein after affinity purification. The blot was separately probed with primary antibody (anti-FREM1 mAb F237G1 targeting CSPG9 domain of FREM1) to identify the full-length FREM1 protein from affinity-purified protein of patients' plasma (patient -1[ML002492], -2[ML002802], -3[ML002442], -4[ML000326], -5[ML002170], -6[ML002443], -7[ML2292], -8[ML2772], -9[ML000109], -10[ML000887], -11[ML000893], and -12[ML001070]). **A-B**) Figure A shows the blot for group-1, -2, and -4 and Figure B for group-3. No band of ~235 kDa was detected (indicated by a white-colored arrowhead). **C-D**) Corresponding gels were used to transfer proteins onto the nitrocellulose membrane. Western blot and Coomassie blue staining images were acquired by Odyssey CLx imaging system (LI-COR, USA) with auto channels (both 700 and 800), 42 μ m resolution, high image quality, and 0 mm focal offset for blots and 0.5 mm focal offset for gels. Patients' ID# and groups are mentioned on the top of the blots. FREM1, Fras-related extracellular matrix 1; ID#, identification number; and kDa, kiloDalton.



Full-length un-cropped blot (Lanes 9-15 probed with F237G3 mAb). Lanes 1-8 used for other purposes. This membrane was cut into two pieces and lanes 9-15 were incubated with F237G3 mAb.



Full-length un-cropped Gel after transfer (Lanes 9-15 used for F237G3 mAb). Lanes 1-8 used for other purposes.

Figure S7: Full-length un-cropped blot and gel. A) The blot was cut into two pieces and the second piece was incubated with anti-FREM1 F237G3 mAb. A clear band of ~57 kDa (blue-colored arrowhead) rFREM1 spD was observed in all samples. A 70 kDa band (white-colored arrowhead) of TILRR protein is also observed in plasma alone and plasma with spiked rFREM1 spD protein. B) Corresponding gel following iBlot transfer onto Nitrocellulose membrane stained with Coomassie blue. The white arrowhead indicates 70kDa and the blue arrowhead represents ~57 kDa. Western blot and Coomassie blue staining images were acquired by Odyssey CLx imaging system (LI-COR, USA) with auto channels (both 700 and 800), 42 μ m resolution, high image quality, and 0 mm focal offset for blot and 0.5 mm focal offset for gel. Patients' ID# and groups are mentioned on the top of the blots. FREM1, Fras-related extracellular matrix 1; ID#, identification number; and kDa, kiloDalton.

Characteristics (at sample collection)	All subjects (n=640) Median (IQR)	Plasma group 1 (n=186) Median (IQR)	Plasma group 2 (n=303) Median (IQR)	Plasma group 3 (n=19) Median (IQR)	Plasma group 4 (n=132) Median (IQR)	p-value
Age, in years	35 (30-40) (n=624 ^a)	33 (28.5-37) (n=179)	35 (30-40) (n=297)	35 (30-38.75) (n=18)	39 (33-45) (n=130)	0.0142 ^b <0.0001 ^{c,d} 0.0147 ^e
	% (n)	% (n)	% (n)	% (n)	% (n)	
Sexually transmitted infection (STIs)	27.00 (172/637 ^f)	29.03 (54/186)	24.67 (74/300)	42.11 (8/19)	28.03 (37/132)	NS
Genital ulcer	6.12 (39/637 ^g)	5.91 (11/186)	3.67 (11/300)	15.79 (3/19)	10.61 (14/132)	$0.0124^{\rm h}$ $0.0044^{\rm i}$
Oral contraceptive used	22.45 (143/637 ^g)	20.43 (38/186)	21.00 (63/300)	31.58 (6/19)	27.27 (36/132)	NS

^aSamples with known age at the time of collection. Age was unknown for 16-samples.

^bStudent t-test was conducted between group 1 and group 2.

^cStudent t-test was conducted between group 1 and group 4.

^dStudent t-test was conducted between group 2 and group 4.

^eStudent t-test was conducted between group 3 and group 4.

^fSamples with a history of known STIs (Gonorrhea, Syphilis, Chlamydial infection, and bacterial vaginosis). 3-samples do not have a history of STIs.

^gSamples with a history of vaginal discharge, genital ulcer, and use of oral contraceptives. History was unknown for 3-samples.

^hChi-Square test was conducted between group 2 and group 3.

ⁱChi-Square test was conducted between group 2 and group 4.

IQR, interquartile range; n, sample#; NS, not statistically significant

REFERENCES

1. Yuan XY, Liu LR, Krawchenko A, et al. Development of monoclonal antibodies to interrogate functional domains and isoforms of FREM1 protein. *Monoclon Antib Immunodiagn Immunother*. Apr 2014;33(2):129-140.